MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414974 | Name: Piperaquine phosphate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piperaquine phosphate is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the structurally similar antimalarial drug chloroquine.

Chemical Structure

Piperaquine phosphate
Piperaquine phosphate
CAS#85547-56-4 (phosphate)

Theoretical Analysis

MedKoo Cat#: 414974

Name: Piperaquine phosphate

CAS#: 85547-56-4 (phosphate)

Chemical Formula: C29H35Cl2N6O4P

Exact Mass: 0.0000

Molecular Weight: 633.51

Elemental Analysis: C, 54.98; H, 5.57; Cl, 11.19; N, 13.27; O, 10.10; P, 4.89

Price and Availability

Size Price Availability Quantity
10mg USD 500.00 2 Weeks
25mg USD 750.00 2 Weeks
50mg USD 1,125.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
4085-31-8 (free base); 911061-10-4 (tetraphosphate); 85547-56-4 (phosphate)
Synonym
Piperaquine phosphate
IUPAC/Chemical Name
Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-, phosphate
InChi Key
KATNPMSTHHZOTK-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H32Cl2N6.H3O4P/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29;1-5(2,3)4/h2-9,20-21H,1,10-19H2;(H3,1,2,3,4)
SMILES Code
ClC1=CC=C2C(N3CCN(CCCN4CCN(C5=CC=NC6=CC(Cl)=CC=C56)CC4)CC3)=CC=NC2=C1.O=P(O)(O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 633.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cahyaningsih U, Sa'diah S, Syafii W, Sari RK, Maring AJ, Nugraha AB. Antimalarial Efficacy of Aqueous Extract of Strychnos ligustrina and Its Combination with Dihydroartemisinin and Piperaquine Phosphate (DHP) against Plasmodium berghei Infection. Korean J Parasitol. 2022 Oct;60(5):339-344. doi: 10.3347/kjp.2022.60.5.339. Epub 2022 Oct 21. PMID: 36320110; PMCID: PMC9633154. 2: Millat-Martínez P, Salman S, Moore BR, Baro B, Page-Sharp M, Batty KT, Robinson LJ, Pomat W, Karunajeewa H, Laman M, Manning L, Mitjà O, Bassat Q. Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0018522. doi: 10.1128/aac.00185-22. Epub 2022 Jul 6. PMID: 35862743; PMCID: PMC9380548. 3: Amarachi CS, Attama AA, Onunkwo GC. Assessment of the Anti-Malarial Properties of Dihydroartemisinin- Piperaquine Phosphate Solid Lipid-Based Tablets. Recent Adv Antiinfect Drug Discov. 2022;17(2):103-117. doi: 10.2174/2772434417666220606105822. PMID: 35670344. 4: Arwati H, Bahalwan RR, Hapsari WT, Wardhani KA, Aini KN, Apsari PIB, Wardhani P. Suppressive effect of goat bile in Plasmodium berghei ANKA infection in mice. Vet World. 2021 Aug;14(8):2016-2022. doi: 10.14202/vetworld.2021.2016-2022. Epub 2021 Aug 6. PMID: 34566316; PMCID: PMC8448659. 5: Zhang Y, Greer RA, Song Y, Praveen H, Song Y. In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach. Eur J Pharm Sci. 2021 May 1;160:105771. doi: 10.1016/j.ejps.2021.105771. Epub 2021 Feb 19. PMID: 33617948; PMCID: PMC7894100. 6: Valecha N, Goyal VK, Mishra DN, Das RR, Jauhri N, Bhardwaj AC, Khurana O, Choudhury R, Pandey M, Baliga BS, Ghosh SK, Srivastava B, Soans ST, Bahl RK, Punj A, Roy A, Sharma SK, Nasa A, Jalali RK, Anvikar AR. Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate in comparison with chloroquine phosphate in children with acute uncomplicated Plasmodium vivax malaria: A phase III, randomised, multicentric study. J Vector Borne Dis. 2020 Jul-Sep;57(3):213-220. doi: 10.4103/0972-9062.311781. PMID: 34472504. 7: Funck-Brentano C, Bacchieri A, Valentini G, Pace S, Tommasini S, Voiriot P, Ubben D, Duparc S, Evene E, Felices M, Corsi M. Effects of Dihydroartemisinin- Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation. Sci Rep. 2019 Jan 28;9(1):777. doi: 10.1038/s41598-018-37112-6. PMID: 30692558; PMCID: PMC6349839. 8: Raji JI, Onwuamah CK, Odeigah PGC. Artemisinin-Based Combination Therapy Depressed Mitosis and Induced Chromosome Aberration in Onion Root Cells. J Toxicol. 2018 Aug 23;2018:4671326. doi: 10.1155/2018/4671326. PMID: 30210539; PMCID: PMC6126092. 9: Liu H, Zhou H, Cai T, Yang A, Zang M, Xing J. Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00260-18. doi: 10.1128/AAC.00260-18. PMID: 29784841; PMCID: PMC6105796. 10: Tripura R, Peto TJ, Chea N, Chan D, Mukaka M, Sirithiranont P, Dhorda M, Promnarate C, Imwong M, von Seidlein L, Duanguppama J, Patumrat K, Huy R, Grobusch MP, Day NPJ, White NJ, Dondorp AM. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages. Clin Infect Dis. 2018 Aug 31;67(6):817-826. doi: 10.1093/cid/ciy196. PMID: 29522113; PMCID: PMC6117448. 11: Gargano N, Madrid L, Valentini G, D'Alessandro U, Halidou T, Sirima S, Tshefu A, Mtoro A, Gesase S; Eurartesim Dispersible Study Group; Bassat Q. Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infants. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e00596-17. doi: 10.1128/AAC.00596-17. PMID: 29061746; PMCID: PMC5740378. 12: Toure OA, Mwapasa V, Sagara I, Gaye O, Thompson R, Maheshwar AV, Mishra P, Behra N, Tshefu AK, Das RR, Anvikar AR, Sharma P, Roy A, Sharma SK, Nasa A, Jalali RK, Valecha N; Arterolane Maleate-Piperaquine Phosphate (AM-PQP) Study Team. Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa. Clin Infect Dis. 2017 Oct 30;65(10):1711-1720. doi: 10.1093/cid/cix617. PMID: 29020247. 13: Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akotet M, Tinto H, Bassat Q, Issifou S, Adamy M, Demarest H, Duparc S, Leroy D, Laurijssens BE, Biguenet S, Kibuuka A, Tshefu AK, Smith M, Foster C, Leipoldt I, Kremsner PG, Phuc BQ, Ouedraogo A, Ramharter M; OZ-Piperaquine Study Group. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Med. 2017 Oct 9;15(1):181. doi: 10.1186/s12916-017-0940-3. PMID: 28988541; PMCID: PMC5632828. 14: Pan B, Pei FQ, Ruan CW, Lin RX, Cen YZ, Liu MR, Deng ZH, Ren WF, Liao YB, Li XH. [Diagnosis and Treatment of the First Imported Case of Plasmodium knowlesi Infection in China]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2016 Dec;34(6):513-6. Chinese. PMID: 30141606. 15: Wang HQ, Li T. [Research on the therapeutic effects of drugs on patients with pneumoconiosis in China]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2016 Jul 20;34(7):510-516. Chinese. doi: 10.3760/cma.j.issn.1001-9391.2016.07.008. PMID: 27682486. 16: Cao S, Wang L, Zhu M, Cai L. [Tracing Investigation of a Quartan Malaria Case in Shanghai]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2016 Apr;34(2):150-3. Chinese. PMID: 30124247. 17: Toure OA, Valecha N, Tshefu AK, Thompson R, Krudsood S, Gaye O, Rao BHK, Sagara I, Bose TK, Mohanty S, Rao BS, Anvikar AR, Mwapasa V, Noedl H, Arora S, Roy A, Iyer SS, Sharma P, Saha N, Jalali RK; AM–PQP Study Team; Tiacoh L, Enosse S, Tangpukdee N, Kokolomami J, Ndiaye JL, Rao D, Yumva NN, Sidibe B, Mohanty R, Jha AC, Nyirenda M, Starzengruber P, Swoboda P. A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether- Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa. Clin Infect Dis. 2016 Apr 15;62(8):964-971. doi: 10.1093/cid/ciw029. Epub 2016 Feb 21. PMID: 26908796; PMCID: PMC4803108. 18: Birgersson S, Van Toi P, Truong NT, Dung NT, Ashton M, Hien TT, Abelö A, Tarning J. Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers. Malar J. 2016 Feb 16;15:90. doi: 10.1186/s12936-016-1134-8. PMID: 26879816; PMCID: PMC4754918. 19: Valecha N, Savargaonkar D, Srivastava B, Rao BH, Tripathi SK, Gogtay N, Kochar SK, Kumar NB, Rajadhyaksha GC, Lakhani JD, Solanki BB, Jalali RK, Arora S, Roy A, Saha N, Iyer SS, Sharma P, Anvikar AR. Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. Malar J. 2016 Jan 27;15:42. doi: 10.1186/s12936-016-1084-1. PMID: 26818020; PMCID: PMC4728808. 20: Toure OA, Rulisa S, Anvikar AR, Rao BS, Mishra P, Jalali RK, Arora S, Roy A, Saha N, Iyer SS, Sharma P, Valecha N. Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study. Malar J. 2015 Nov 25;14:469. doi: 10.1186/s12936-015-0982-y. PMID: 26608469; PMCID: PMC4660726.